By Rishika Sadam

HYDERABAD, India (Reuters) – Indian drugmakers aiming to seize a slice of the burgeoning weight-loss remedy gross sales pie, each at residence and overseas, have begun growing their very own variations of Novo Nordisk’s wildly in demand Wegovy.

With some analysts predicting a weight-loss market reaching $100 billion a 12 months or extra by the top of the last decade, executives at Solar Pharma, Cipla, Dr Reddy’s and Lupin — among the world’s largest generic drugmakers — all stated they’ve began work on Wegovy variations.

Novo Nordisk has been unable to provide sufficient Wegovy to satisfy demand in additional than half a dozen nations the place it has already launched, amid document world weight problems charges and folks on the lookout for simpler options to eating regimen and train. U.S. rival Eli Lilly likewise has been unable to satisfy demand for its weight-loss medication Zepbound and Mounjaro.

Novo has not supplied a transparent timeline for introducing Wegovy globally, however instructed Reuters it goals to launch in India in 2026.

The transfer by Indian drugmakers might go a good distance towards enhancing world entry to weight-loss medication and make them much more reasonably priced, analysts stated.

“We anticipate quantity growth to extend multi-fold by the point patent expires, which is a number of years from now,” Systematix analyst Vishal Manchanda stated. “They will even be accessible at a a lot lower cost by generic drugmakers.”

Trade insiders agreed.

“There’s large potential in India… given the approach to life selections,” Cipla International CEO Umang Vohra stated in a post-earnings name in January.

India has excessive weight problems charges, particularly amongst girls, and has the world’s second highest variety of individuals with sort 2 diabetes, trailing solely China. Round 11% of adults in India might be overweight by 2035, based on the World Weight problems Federation Atlas.

Novo’s patents for Wegovy, given as a weekly injection, expire in China in 2026, in Japan and Europe in 2031, and within the U.S. in 2032, based on its annual report.

The Danish drugmaker is the only real patent holder of semaglutide, the energetic ingredient in Wegovy and diabetes remedy Ozempic, which aren’t but authorized in India. It declined to touch upon when its patent would expire in India.

“We wish to market this product on time in all of the markets as (Novo’s) patent expires,” Dr Reddy’s CEO Erez Israeli stated of semaglutide in a media name final month.

Novo didn’t touch upon when it expects to see competitors from Indian drugmakers however instructed Reuters it “welcomes new remedy choices” for individuals residing with weight problems.

DEVELOPING A MARKET

Solar Pharma is working by itself experimental drug to deal with sort 2 diabetes and weight problems. Others are taking a extra conventional generic drug path.

“Dr. Reddy’s and Cipla are making a duplicate of the innovator drug extra like a generic model, whereas Solar is working by itself innovator drug. So, Solar must do scientific trials. Its drug might be novel and patented,” Manchanda stated.

The Indian marketplace for diabetes medication alone was estimated at 316 billion rupees ($3.81 billion) in 2023 and is projected to hit 1.2 trillion rupees ($14.48 billion) within the subsequent decade, based on Knowledgeable Market Analysis.

Wegovy in scientific trials helped sufferers lose as much as 15% of their physique weight, whereas Eli Lilly drug trial individuals misplaced much more. Their medicines belong to a category of therapies referred to as GLP-1 receptor agonists initially developed to manage blood sugar in sort 2 diabetes sufferers. In addition they sluggish digestion, serving to individuals really feel full longer.

Information exhibiting the category of medicine may additionally delay development of persistent kidney illness and decrease coronary heart illness dangers are more likely to additional enhance demand.

Regardless of the house turf benefit for firms like Cipla, cracking the price-sensitive Indian market will not be simple.

“In India, the requirement is to develop a marketplace for anti-obesity (medication),” stated DAM Capital analyst Nitin Agarwal, “in contrast to in different nations the place drugmakers can simply take a share of present market.”

($1 = 82.8700 Indian rupees)

(Reporting by Rishika Sadam; Enhancing by Dhanya Skariachan and Invoice Berkrot)

At this time Information Prime Newsmaac

LEAVE A REPLY

Please enter your comment!
Please enter your name here